0 COVID-19: success seen in Synairgen inhalable drug trial
In collaboration with the University of Southampton, Synairgen (both Southampton, UK) have announced positive results from their recent trial of SNG001, a novel protein based COVID-19 drug.
Browsing: Basic > Drug Development
0 Four new compounds identified for COVID-19 drug repurposing
In a collaborative study between the University of South Florida (USF Health; FL, USA) and the University of Arizona College of Pharmacy (AZ, USA), several existing drugs have been identified as potential therapies for COVID-19.
0 Antiviral strategies for emerging infectious diseases: Cayman Chemical
The emergence and global spread of SARS-CoV-2 has prompted scientific study on an unprecedented scale, with an urgent need for…
0 Confronting COVID-19 head on at the Wyss Institute
Harvard’s Wyss Institute is leveraging its unique technology innovation capabilities to develop diagnostic, therapeutic, and vaccine interventions for COVID-19 at lightning speed.
0 Researchers identify inflammatory molecules as potential targets for COVID-19
Researchers have accurately profiled the immune response to COVID-19 in critically ill patients, allowing them to identify six inflammatory molecules as potential targets for COVID-19 treatment.
0 Could RBX2660 be the microbiome-based solution to C. diff infection recurrence?
Rebiotix (MN, USA) recently announced positive preliminary results from an ongoing clinical trial investigating the use of an investigational microbiota-based formulation, RBX2660, for the reduction of C. diff infection.
0 A peek behind the paper – John Nemunaitis on targeting furin to tackle SARS-CoV-2
Take a look behind the scenes of a recent Future Virology paper, titled ‘Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: Let the…
0 COVID-19 research round-up: May
This month’s research round-up covers a number of studies investigating hydroxychloroquine, along with a remdesivir study, the first Phase I vaccine clinical trial and an exploration of the burden of COVID-19 on the healthcare system.
0 Resistance-free ‘poisoned arrow’ antibiotic kills Gram-negative bacteria
Researchers from Princeton University have uncovered an antibiotic molecule capable of killing both Gram-negative and Gram-positive bacteria using two simultaneous mechanisms, while also avoiding antibiotic resistance.
0 Drug repurposing study uses live virus to identify 30 potential COVID-19 candidates
A drug repurposing survey has identified 30 existing drugs, previously approved for treatment in other diseases, that could be successful in treating COVID-19.
